Publications

PUBLICATIONS    this is a list of publications derived from work at least partially supported by the Foundation:

Rendell M:  Editorial:   Dietary treatment of diabetes mellitus.  N Engl J Med 342: 1440-              1441,   2000

Rendell MS,  Kirchain WR:  Drug treatments in type 2 diabetes mellitus.  Annals of Pharmacotherapy  34: :878-95, 2000.

Apfel SC, Asbury AK,  Bril V,  Burns TM, Campbell JN, Chalk CH, Dyck PJ, Dyck PJB, Feldman EL,   Fields HL, Grant IA, Griffin JW, Klein CJ, Lindblom U, Litchy WJ, Low PA Melanson M, Mendell JR, Merren MD, O’Brien PC, Rendell M, Rizza RA, Service FJ,  Thomas PK, Walk D, Wang AK, Wessel K, Windebandk AJ, Ziegler D, Zochodne DW:   Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials.  Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials.   J Neurol Sci   189: 3-5, 2001

Rendell M,   Johnson ML,   Smith D,   Finney D,     Capp C,  Lammers R,    Lancaster S:   The Skin Blood Flow Response in the Rat Model of Wound Healing:   Expression of Vasoactive Factors J Surg Res 107: 18-26 (2002)

Rendell M, Cariski AT, Hittel N, Zhang P:  Cilostazol treatment of claudication in diabetic patients.   Curr Med Res Opin  18:  479-487,   2002

Rendell M, Anderson E, Schlueter W, Mailliard J, Honigs D, Rosenthal R. Determination of hemoglobin levels in the finger using near infrared spectroscopy.  Clin Lab Haematol. 2003; 25:93-97, 2003.

Rendell M, Glazer NB, Ye Z:   Combination Therapy with Pioglitazone Plus Metformin or Sulfonylurea in Patients with Type 2 Diabetes: Influence of Prior Antidiabetic Drug Regimen.  J Diab Complications 17: 211-217, 2003.

Riddle MC, Rosenstock J, Gerich J,   Rendell M as part ot the Insulin /Glargine 4002 Study Investigator Group: The Treat to Target Trial.  Randomized addition of glargine or human NPH insulin to oral therapyof type 2 diabetic patients.   Diab Care 26: 3080-3086,  2003

 Rendell M,  Saxena S,  Shah D: Cutaneous blood flow and peripheral resistance in Type II Diabetes as compared to  intermittent claudication patients.    Int J Angiology 12: 166-171, 2003

Capp CL,  Dorwart WC,  Elias NT,  Hillman SR,. Lancaster SS,  Nair RC,  Ngo BT,  Rendell MS,  Smith DM:  Post Pressure Hyperemia in the Rat.  Comp Biochem Physiol  A Mol Integr Physiol.  137:533-546, 2004

Rendell M:   Type 2 Diabetes Management in the Elderly      Clin Geriatrics 12: 43-52, 2004

Bergren DR, Rendell MS:   Depressed ventilatory reflexes in response to capsaicin challenge in streptozotocin treated rats.  Life Sciences 75: 2103-2116, 2004

Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 64:1339-58, 2004.

Rendell M,   Lundberg GD:. Advances In Diabetes For The Millennium: An e-Symposium. Medscape General Medicine. 2004;6(2). Available at: http://www.medscape.com/viewarticle/484719.

Rendell M:  Advances in Diabetes for the Millennium: Nutritional Therapy of Type 2 Diabetes.   Medscape General Medicine. 2004; 6(3s). Available at: http://www.medscape.com/viewprogram/3378.

Rendell M: Advances in Diabetes for the Millennium: Drug Therapy of Type 2 Diabetes.   Medscape General Medicine Available at:http://www.medscape.com/viewprogram/3410.

Wigington G, Ngo B, Rendell M: Skin blood flow in diabetic dermopathy.  Arch Dermatol. 140:1248-50,  2004

Ngo BT, Hayes KD, DiMiao DJ, Srinivasan SK, Huerter CJ, Rendell MS.  Manifestations of cutaneous diabetic microangiopathy.Am J Clin Dermatol. 2005;6(4):225-37.

Rendell M, Vanderhoof J, Venn M, Shehan MA, Arndt E, Rao CS, Gill G, Newman RK, Newman CW. Effect of a barley breakfast cereal on blood glucose and insulin response in normal and diabetic patients. Plant Foods Hum Nutr. 2005;60:63-67.

Rendell M: Post-prandial hyperglycemia: Why do we care about it?  What should we do? Drug Develop Res 2006;  67: 1-5

Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia.  Metabolism. 2006;   55: 1263-1281.

Rendell M, Gurwitz D: Metabolic syndrome: a wake-up call. Drug Develop Res 2006; 67: 535-538

Shah P, Ngo B, Rendell M: Bleeding toes in diabetic neuropathy.Am J Med. 2007; 120: e1-e2

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31:30-35.

Ngo B, Wigington G, Hayes, K,.  Huerter,, C,  Hillman B, Adler, M,  Rendell, M. Skin blood flow in necrobiosis lipoidica diabeticorum.  Int J Derm 47: 354-358.2008

Rendell M: New drug options for managing diabetes.  Diabetes Trends 20: 18-26, 2008

Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.  Diabetes Care. 31:1305-1310, 2008

Bonebrake R, Casey MJ, Huerter C, Ngo B, O’Brien R, Rendell M.Ethical challenges of pregnancy prevention programs.  Cutis 81:494-500,  2008

Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin Glargine: a review 8 years after its introduction. Expert Opin Pharmacother  10:705-718, 2009

Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 11:1145-1152, 2009

Andukuri R, Drincic A, Rendell M:  Alogliptin: a new addition to the class of DPP-4 inhibitors.  Diabetes, Metabolic Disease and Obesity 2: 117 – 126,  2009

Bansal A, Chamberlain R, Karr S, Kwasa S, McLaughlin B, Nguyen B, Rendell M, Schmit K, Smith C. A 21 CFR Part 11 Compliant Graphically Based Electronic System for Clinical Research Documentation.  J Med Syst. 2010 Nov 25. [Epub ahead of print]PMID: 21107888

Ngo B, Rongey C, Hiscox B, Rendell M, Woodley D, Smogorzewski M. Skin blood flow in patients with stage 5 chronic kidney disease on hemodialysis.  J Ren Nutr. 2010 Sep;20(5 Suppl):S89-94.

Rendell M, Chrysant SG. Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Postgrad Med. 2011 Jul;123(4):183-186

Brugler A, Thompson S, Turner S, Ngo B, Rendell M.  Skin blood flow abnormalities in diabetic dermopathy.  J. Am Acad Dermatol. 2011 Sep;65(3): 559-63

Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M.  Influence of preprandial versus postprandial insulin glulisine on weight and glycemic control in patients initiating basl-bolus regimen for type 2 diabetes:  a multicenter, randomized, parallel, open-label study (NCT00135096).  Diabetes Obex Metab.  2011; 13(12):1142-8 PMID:  21812890

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr., Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG;  Protégé Trial Investigators.  Teplizumab for treatment of type 1 diabetes (Protégé study):  1-year results from a randomized, placebo-controlled trial.  Lancet.  2011 Aug 6; 378(9790):487-97.

Rendell M, Drincic A, Andukuri R.  Alogliptin benzoate for the treatment of type 2 diabetes.  Expert Opin Pharmacother.  2012 Mar:13(4):553-63.

Casey MJ, O’Brien R, Rendell M, Salzman T.  Ethical dilemma of mandated contraception in pharmaceutical research at Catholic medical institutions.  Am J Bioeth. 2012;12(7):34-37. PMID:22694032

Catalona JU, D’Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC.  What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.  Ann Intern Med. 2012 May 21. (Epub ahead of print)

Belzowski A, et al., The effect of vasoactive agents on post-pressure hyperemia, Microvasc. Res. (2012), http://dx.doi.org/10/1016/j.mvr.2012.07.001

Rendell M.   Of  rights and the rules. Obamacare and the challenge of diabetes.  Collier’s Magazine. October, 2012

Rendell S, Kosoko-Lasaki O, Penny G, Cook CT, Sharma A, Austin WP, Rendell M. Improved quality of life in unselected insulin pump-treated children with Type 1 Diabetes in Eastern Nebraska. J Diabetes Sci Technol. 2013 7(2):579-581.

Rendell M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf. 2013 Mar;12(2):195-207.

Rendell M, Akturk HK, Tella SH. Glargine safety, diabetes and cancer. Expert Opin Drug Saf. 2013 Mar;12(2):247-63.

)Rendell M. Diabetes. New drug options and old choices.  Consultant 2013 April 53(4): 217-227

 

Rendell M, Saiprasad S, Trepp-Carrasco AG, Drincic A.  The future of inpatient diabetes management: glucose as the sixth vital sign. Expert Rev. Endocrinol Metab 8(2), 195-205 (2013)

Lawson C, Larson K, Van Erdewyck J, Smith C, Rizzo A,  Ross L.  A facilitated interface to generate a combined textual and graphical database system using widely available software. J Software Engin & Applic 5: 789-796 ( 2012)

Zimmer EA, Welie JVM, Rendell MS: Contraceptives and the Law:  A view from a Catholic medical institution.  JAMA 309(19) 1999-2000, 2013

Rendell M: Insulin degludec: a long-acting modern insulin analog with a predictable pharmacokinetic/pharmacodynamic profile. Drugs of Today 49(6) 387-397

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.  A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs. 2013 Jul;73(10):1025-54.

Moul JW, Walsh PC, Rendell MS, Lynch HT, Leslie SW, Kosoko-Lasaki O, Fitzgibbons WP, Powell I, D’Amico AV, Catalona WJ. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.  J Urol. 2013 Sep;190(3):1134-7.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; Rendell M as part of EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35

Rendell M, Welie JV, Zimmer EA. Controversy over contraception coverage–reply. JAMA. 2013 Sep 25;310(12):1289. doi: 10.1001/jama.2013.276776. PMID: 24065024

Tella SH, Akturk HK, Rendell M. Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4 (1) 85-101 (2014).

Beland K , Larson K, T Rowley T, Mueller M, Smith C, Rizzo A, Valandra D, Rendell M. Security and audit trail capabilities of a facilitated interface used to populate a database system with text and graphical data using widely available software. J Software Engineering & Applications, 2014, 7, **-** Published Online July 2014 in SciRes. http://www.scirp.org/journal/jsea

Technosphere inhaled insulin (Afrezza). Rendell M. Drugs Today (Barc). 2014;50(12):813-27

Tarasova VD, Zena M, Rendell M. Artifactual hypoglycemia: an old term for a new classification. Diabetes Care. 2014 May;37(5):e85-6.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94.

 Tella SH, Rendell MS.DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf. 2015 Jan;14(1):127-40

 Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab. 2015; 63:109-134

 Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul;38(7):1181-8

 Rendell M. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes. Drugs Today (Barc). 2015 Mar;51(3):185-96.

 Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Jul 20

 Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I. Screening for Familial and Hereditary Prostate Cancer. Int J Cancer. 2015 Dec 5. doi: 10.1002/ijc.29949. [Epub ahead of print] Review.

 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; Rendell M as EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720

Lynch HT, Rendell M, Shaw TG, Silberstein P, Ngo BT.Commentary on Almassalha et al., “The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer”.Cancer Res. 2016 Oct 1;76(19):5602-5604. Epub 2016 Sep 16.PMID: 27638875

Paknikar S, Sarmah R, Sivaganeshan L, Welke A, Rizzo A, Larson K, Rendell M.Long-term performance of point-of-care Hemoglobin A1c assays. J Diabetes Sci Technol. 2016 Nov 1;10(6):1308-1315. Print 2016 Nov.PMID: 2711345